Multi Blockbuster Share??, page-54

Morning NZT, I don't think many of the top 100 would be selling up at 30c. We've waited too long and the evidence is too strong now to take a low-ball offer. Pfizer just wouldn't get the numbers IMO.
I'd love clarification on the word "stable" from Dr Mathers. Surely if a patient's symptoms are not progressing you do not increase the dose? How come then was a stable patient from cohort 1 put into cohort 2, with stated plans to put same patient into cohort 4. I maybe getting too excited here but are they hoping to reverse existing damage to cells? I.e. not just stop progression but "cure" some existing symptoms as well? Maybe hoping to get patients back to a "near normal" standard of health? I'm sure this would not be possible if this terrible affliction has had time to run rampant in a patient, but maybe with the newly diagnosed? Wow, I hope so!